Key result
Triiodothyronine alleviates sepsis-induced cardiomyopathy by inhibiting phospholamban, which yields ~0.95 AUC for diagnosis.
Why the study?
Does triiodothyronine alleviate myocardial injury in sepsis-induced cardiomyopathy?
Does triiodothyronine alleviate myocardial injury in sepsis-induced cardiomyopathy?
Effect estimate: AUC 0.9503 (95% CI 0.9014-0.9993)
Triiodothyronine protects against sepsis-induced cardiomyopathy by downregulating phospholamban, highlighting PLN as a potential diagnostic marker.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2025) studied Sepsis-induced cardiomyopathy (SIC) (n=86). Triiodothyronine (T3) vs. LPS (sepsis model) / Healthy controls was evaluated on Diagnostic performance of serum phospholamban (PLN) for SIC (AUC 0.9503, 95% CI 0.9014-0.9993). Triiodothyronine alleviated myocardial injury in sepsis-induced cardiomyopathy by inhibiting phospholamban, which also demonstrated excellent diagnostic performance for SIC with an AUC of 0.9503.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: